FL-XLEAR
2.12.2020 10:34:38 CET | Business Wire | Press release
New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains...” The Virucidal studies were independently funded.
“The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said Dr. Gustavo Ferrer, who is leading the research team.
State of scientific research:
Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19. Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19). https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2768627 .
Xlear’s components are antiviral—they block viral adhesion in the nose . See, for example, https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full.pdf . This Univ. of Tennessee study on SARS-CoV-2 concluded: “antiviral nasal sprays...contribute reduce...viral load...slowing down disease progression...and transmission...”
Peer-reviewed case studies indicate Xlear helps in treating COVID-19: First-look trial at Larkin Community Hospital (Miami), determined: “symptomatic, COVID-19 patients, treated with [Xlear], as an adjunct to...[standard care],” showed “rapid clinical improvement and shorten[ed] time” to negative COVID-19 PCR tests. https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extract-nasal-spray-solution-in-covid-19-case-series .
Xlear has been used for over 20 years by millions of people worldwide without a single significant adverse incident report.
“Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2). This combination of antiviral and virucidal capabilities is an important one-two punch in fighting the virus,” said Nathan Jones, CEO of Xlear. “With the pandemic raging worldwide, we must use every tool we can to fight it. Failing that needlessly risks millions of lives. Weighing our 20-year safety record, against the risks of this deadly virus, it’s clear Xlear needs to be in widespread use,” Jones concluded.
Full study: https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
More information on Xlear: https://xlear.com/
About Dr. Gustavo Ferrer
Dr. Ferrer, MD FCCP, is an Associate Professor of Medicine and Founder of the Cleveland Clinic Florida Interstitial Lung Disease Clinic and the Aventura Hospital Pulmonary and Critical Care fellowship. He currently serves as President of Intensive Care Experts/Aventura Pulmonary Institute and previously served as United Nations University Director of Respiratory Research, Venezuela.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005291/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 04:00:00 CEST | Press release
— Advancing JTB's “Departing Globally, Arriving Globally” Vision — JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom